



PIONEERING RESEARCH.

Developing therapeutic and diagnostic products for neurological disorders and orphan indications.

ESS TESTIMONIAL




"The fact that this product is not on (the) market is the biggest disappointment of my career".

Dr. David H. Ahrenholz
Former President, American Burn Association

ESS TECHNOLOGY



MANF



AMARANTUS BIOSCIENCE HOLDINGS, INC.: A RICH PIPELINE FOCUSED ON ACCELERATING VALUE CREATION

Amarantus BioScience Holdings, Inc. is a public biotechnology company (OTCQX: "AMBS") that has a pipeline of novel clinical and preclinical stage therapies for high unmet need indications such as Parkinson's Disease, retinitis pigmentosa, retinal artery occlusion and severe burns, the last three having acquired Orphan Drug Designations from the FDA. The company also has a pipeline of diagnostics for detecting the early stages of Multiple Sclerosis, Alzheimer's and potentially Chronic Traumatic Encephalopathy, and which are being readied for strategic transactions and spin-off. Amarantus' main focus is on drug therapies and diagnostics that are undervalued in the market that can be monetized quickly through fast-track FDA orphan drug and/or rare pediatric disease development pathways.

AMBS THERAPEUTICS DIVISION PIPELINE

- **ENGINEERED SKIN SUBSTITUTE (Severe Burns, Orphan Designation)**
 - ESS is a full-thickness 'sheet' of skin produced from a patient's own cells that are grown in culture
 - GMP manufacturing by Lonza
 - Entering Phase 2 clinical trials in collaboration with US Army, 1Q 2016
 - ESS positioned for entry into pivotal trials for other severe dermatologic conditions that are rare and primarily affect pediatric patients, 2H 2016
 - Strong support from two past presidents of the American Burn Association; Principal Investigator is incoming ABA president
- **ELTOPRAZINE (Parkinson's (PD-LID), Orphan Designation Submitted)**
 - Small compound in clinical Phase 2b development
 - Initial target is Parkinson's disease levodopa-induced dyskinesia
 - Potential to expand into adult ADHD and Alzheimer's aggression based on results of previous clinical studies
- **MANF (Retinitis Pigmentosa, Retinal Artery Occlusion; Orphan Designations)**
 - Mesencephalic Astrocyte-derived Neurotrophic Factor
 - Recombinant human protein, discovered at AMBS using proprietary discovery engine
 - Preclinical asset currently positioned as a treatment for orphan ophthalmic indications with potential expansion into neurology and additional orphan diseases

AMBS DIAGNOSTICS DIVISION


The company also has a pipeline of diagnostics for detecting the early stages of Multiple Sclerosis, Alzheimer's and potentially Chronic Traumatic Encephalopathy,

and which are being *readied for strategic transactions and spin-off*.

MS PRECISE

MSPrecise:
HIGH RESOLUTION TECHNOLOGY



Next Generation Sequence Analysis of Rare
Antibody Genes



AGT GGG AGC ACC TAC TAC AAC

+ PREDICTIVE VALUE ~ 80%

LYMPRO



- **MS PRECISE** (First in Class Molecular Diagnostic for Multiple Sclerosis)
 - Positioned as a rule in/rule out diagnostic for Relapsing-Remitting Multiple Sclerosis for which the standard testing procedures exhibit suboptimal predictive value
 - Technology is based on Next Generation sequence analysis of very rare antibody genes
 - CLIA launch planned for 2017
- **LYMPRO** (First in Class, Blood Based Test for Alzheimer's Disease)
 - Blood-based test based on measurement of fundamental cell-cycle dysfunction in Alzheimer's Disease
 - Positioned to offer effective diagnostic for early stages of Alzheimer's
 - Potential applicability to Chronic Traumatic Encephalopathy

PHASE 1-2 PIPELINE

	Program	Preclinical	Phase 1	Phase 2	Phase 3
Orphan Designation	ESS Pediatric 50%+ TBSA Stage 3&4 Burns	[Progress bar]			
	ESS Congenital Giant Hairy Nevus	[Progress bar]			
	ESS Adult 50%+ TBSA Stage 3&4 Burns	[Progress bar]			
Orphan Application	Eltoprazine Adult ADHD	[Progress bar]			
	Eltoprazine Parkinson's L-Dopa induced Dyskinesia	[Progress bar]			
	Eltoprazine Alzheimer's Aggression	[Progress bar]			

EXECUTIVE TEAM

Gerald E. Commissiong, Co-Founder, President & CEO, Director

- Founded AMBS in 2008
- Professional athlete: CFL Calgary Stampeders
- Stanford University, Management Science & Engineering

Robert Farrell, JD, Chief Financial Officer

- CEO and CFO at Titan Pharmaceuticals
- CFO, Group Vice President and General Counsel of Fresenius
- CFO, Institute for One World Health (Gates Foundation, others)

Elise Brownell, PhD, Sr. Vice President Project Management & Operations

- Founding Partner, ZephyrBiotech, LLC
- Head of Project Management, Aerovance, Inc
- Head of Project Management at Bayer Biotechnology
- Yale University, PhD in Biology

Ravi Kiron, PhD, MBA, Sr. Vice President Corporate & Business Development

- CoFounder C2N Diagnostics, Navya Biomedical Technologies
- Executive Management positions at Pfizer, Johnson & Johnson (ALZA)
- Asst. Professor of Biochem. & Medicine, Cornell University, New York
- Indian Institute of Science, PhD Biochemistry; Rensselaer NY, MBA